Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Equillium

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Immunology Product Name: Alzumab

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 06, 2020

            Details:

            The EQUATE trial is evaluating itolizumab in severe aGVHD patients concomitant with standard of care, which is typically comprised of high dose corticosteroids, as no other therapeutics are currently approved for this indication.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Immunology Product Name: EQ001

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biocon Limited

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 04, 2020

            Details:

            Data will be presented demonstrating that modulation of the CD6-ALCAM pathway with itolizumab improves kidney and skin pathology in mouse models of SLE.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Infections and Infectious Diseases Product Name: EQ001

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biocontrolled

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 29, 2020

            Details:

            Itolizumab is a first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. Patients enrolled in EQUINOX trial will be randomized 1:1 to receive either itolizumab or placebo in addition to best supportive care for the treatment for Covid-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EQ001

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 17, 2020

            Details:

            These findings suggest the CD6-ALCAM pathway may contribute in multiple ways to asthma pathology. These data support Equillium’s ongoing clinical development of itolizumab for the treatment of patients with moderateto-severe uncontrolled asthma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Infections and Infectious Diseases Product Name: EQ001

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 15, 2020

            Details:

            The FDA provided positive feedback supporting Equillium’s clinical development plans for evaluating itolizumab (EQ001) as a potential treatment for hospitalized patients with COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Immunology Product Name: Alzumab

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 10, 2020

            Details:

            Across the first two dose cohorts itolizumab has been generally well tolerated to date, and five of seven patients achieved a complete response (CR) by Day 29.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Infections and Infectious Diseases Product Name: Alzumab

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biocon Limited

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 13, 2020

            Details:

            Biocon has received emergency use approval from Drugs Controller General of India for itolizumab in the treatment of CRS in COVID-19 patients with moderate to severe ARDS.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Itolizumab

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 30, 2020

            Details:

            The research, conducted in mouse models, demonstrates that blockade of the CD6-ALCAM pathway with anti-CD6 antibodies reduces incidence and severity of both GVHD and gastro-intestinal inflammation.